BIOGEN INC (1BIIB.MI) Fundamental Analysis & Valuation
BIT:1BIIB • US09062X1037
144.45 EUR
-6.45 (-4.27%)
Last: Jan 15, 2026, 07:00 PM
This 1BIIB.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, 1BIIB scores 6 out of 10 in our fundamental rating. 1BIIB was compared to 75 industry peers in the Biotechnology industry. 1BIIB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. 1BIIB is cheap, but on the other hand it scores bad on growth. This makes 1BIIB very considerable for value investing!
1. 1BIIB.MI Profitability Analysis
1.1 Basic Checks
- In the past year 1BIIB was profitable.
- 1BIIB had a positive operating cash flow in the past year.
- Each year in the past 5 years 1BIIB has been profitable.
- Each year in the past 5 years 1BIIB had a positive operating cash flow.
1.2 Ratios
- 1BIIB has a better Return On Assets (5.51%) than 82.95% of its industry peers.
- The Return On Equity of 1BIIB (8.84%) is better than 81.82% of its industry peers.
- With an excellent Return On Invested Capital value of 9.70%, 1BIIB belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for 1BIIB is in line with the industry average of 12.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- With an excellent Profit Margin value of 15.98%, 1BIIB belongs to the best of the industry, outperforming 82.95% of the companies in the same industry.
- 1BIIB's Profit Margin has declined in the last couple of years.
- 1BIIB's Operating Margin of 28.50% is amongst the best of the industry. 1BIIB outperforms 86.36% of its industry peers.
- In the last couple of years the Operating Margin of 1BIIB has declined.
- With a decent Gross Margin value of 75.24%, 1BIIB is doing good in the industry, outperforming 67.05% of the companies in the same industry.
- 1BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. 1BIIB.MI Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1BIIB is creating some value.
- 1BIIB has more shares outstanding than it did 1 year ago.
- 1BIIB has less shares outstanding than it did 5 years ago.
- 1BIIB has a better debt/assets ratio than last year.
2.2 Solvency
- 1BIIB has an Altman-Z score of 3.25. This indicates that 1BIIB is financially healthy and has little risk of bankruptcy at the moment.
- 1BIIB's Altman-Z score of 3.25 is fine compared to the rest of the industry. 1BIIB outperforms 70.45% of its industry peers.
- The Debt to FCF ratio of 1BIIB is 2.78, which is a good value as it means it would take 1BIIB, 2.78 years of fcf income to pay off all of its debts.
- 1BIIB has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. 1BIIB outperforms 84.09% of its industry peers.
- 1BIIB has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- 1BIIB has a Debt to Equity ratio of 0.35. This is comparable to the rest of the industry: 1BIIB outperforms 59.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.25 |
ROIC/WACC1.16
WACC8.36%
2.3 Liquidity
- 1BIIB has a Current Ratio of 2.72. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.72, 1BIIB perfoms like the industry average, outperforming 57.95% of the companies in the same industry.
- 1BIIB has a Quick Ratio of 2.04. This indicates that 1BIIB is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.04, 1BIIB is in line with its industry, outperforming 47.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. 1BIIB.MI Growth Analysis
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- 1BIIB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
- Looking at the last year, 1BIIB shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
- The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. 1BIIB.MI Valuation Analysis
4.1 Price/Earnings Ratio
- 1BIIB is valuated reasonably with a Price/Earnings ratio of 10.13.
- Compared to the rest of the industry, the Price/Earnings ratio of 1BIIB indicates a rather cheap valuation: 1BIIB is cheaper than 96.59% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.83. 1BIIB is valued rather cheaply when compared to this.
- 1BIIB is valuated reasonably with a Price/Forward Earnings ratio of 10.98.
- 1BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 97.73% of the companies in the same industry.
- 1BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.95.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.13 | ||
| Fwd PE | 10.98 |
4.2 Price Multiples
- 1BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 94.32% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, 1BIIB is valued cheaply inside the industry as 96.59% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11 | ||
| EV/EBITDA | 7.46 |
4.3 Compensation for Growth
- 1BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
5. 1BIIB.MI Dividend Analysis
5.1 Amount
- 1BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1BIIB.MI Fundamentals: All Metrics, Ratios and Statistics
BIT:1BIIB (1/15/2026, 7:00:00 PM)
144.45
-6.45 (-4.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/amc
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap21.19B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target163.34 (13.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.01%
PT rev (3m)10.35%
EPS NQ rev (1m)1.04%
EPS NQ rev (3m)-53.64%
EPS NY rev (1m)-1.67%
EPS NY rev (3m)-5.23%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-2.21%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.13 | ||
| Fwd PE | 10.98 | ||
| P/S | 2.47 | ||
| P/FCF | 11 | ||
| P/OCF | 10.14 | ||
| P/B | 1.37 | ||
| P/tB | 10.43 | ||
| EV/EBITDA | 7.46 |
EPS(TTM)14.26
EY9.87%
EPS(NY)13.16
Fwd EY9.11%
FCF(TTM)13.13
FCFY9.09%
OCF(TTM)14.24
OCFY9.86%
SpS58.44
BVpS105.7
TBVpS13.85
PEG (NY)N/A
PEG (5Y)N/A
Graham Number184.16
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.25 |
F-Score5
WACC8.36%
ROIC/WACC1.16
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.36%
EPS Next 2Y-3.15%
EPS Next 3Y-0.51%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.98%
Revenue Next 2Y-1.62%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / 1BIIB.MI FAQ
What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI.
What is the valuation status of BIOGEN INC (1BIIB.MI) stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.
Can you provide the profitability details for BIOGEN INC?
BIOGEN INC (1BIIB.MI) has a profitability rating of 7 / 10.
What are the PE and PB ratios of BIOGEN INC (1BIIB.MI) stock?
The Price/Earnings (PE) ratio for BIOGEN INC (1BIIB.MI) is 10.13 and the Price/Book (PB) ratio is 1.37.
What is the expected EPS growth for BIOGEN INC (1BIIB.MI) stock?
The Earnings per Share (EPS) of BIOGEN INC (1BIIB.MI) is expected to decline by -7.36% in the next year.